Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients

Mutations in the drug binding region of BCR-ABL lead to imatinib resistance during the management of chronic myeloid leukemia (CML). In our study, 62 Philadelphia positive (Ph(+)) CML patients showing conspicuous expression of BCR-ABL gene were treated with imatinib. At the end of 3 months, 21/62 (3...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekhar, Chodimella, Kumar, Pasupuleti Santhosh, Sarma, Potukuchi Venkata Gurunadha Krishna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382822/
https://www.ncbi.nlm.nih.gov/pubmed/30787317
http://dx.doi.org/10.1038/s41598-019-38672-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382822/
https://www.ncbi.nlm.nih.gov/pubmed/30787317
http://dx.doi.org/10.1038/s41598-019-38672-x

Ejemplares similares